The Clinical Core is integral to Duke CFAR activities by providing access for investigators to specified and carefully characterized populations of people with HIV (PWH); providing expert assistance in study design, implementation, and regulatory support; identifying new scientific opportunities based upon novel clinical observations; promoting interdisciplinary team science; and engaging investigators new to HIV/AIDS research. We emphasize bidirectional communication and engagement with communities of researchers and PWH in North Carolina and Tanzania through our Community Advisory Boards (CABs).

If you would like to request a service from the Clinical Core, please fill out this Service Request Form and email it to

The Clinical Core services fall into 5 broad categories:
Consultation on study design, implementation, analysis and manuscript preparation
Drs. Dow, Le, Okeke and McKellar are highly experienced clinical investigators, and their experience offers a great service to laboratory-based investigators and junior investigators who need human subjects for their research. They average 30 consultations on studies per year. These consultations may provide input on study design, study interventions, study outcome measures, appropriate subject populations, project implementation, adverse events, study analysis, interpretation of results, and publication of manuscripts.  

Clinical Research Support
The Clinical Core can assist with a number of issues related to the conduct of specific research studies. This may include consultations on study design, study feasibility and recruitment and retention issues. In addition, study coordinator assistance may be available for some studies. Salary support is requested for study coordinator assistance whenever possible. Stuart Carr has been working with various study teams on these issues for a number of years.
Regulatory Support    
Regulatory compliance is essential by all Duke CFAR investigators, and the Clinical Core provides expertise and assistance in ensuring compliance.  Regulatory support is the service most commonly requested by Clinical Core Users, and approximately 100 users access this service annually.  Given the number of international studies and the number of countries in which CFAR investigators are engaged in research, the management of regulatory compliance has become enormously complex. The CFAR Clinical Core can assist international partners with requirements for DUHS IRB submissions, human subject protection training, and other specific requirements related to their research. Stuart Carr and Kathy Link have many years of regulatory experience working with various types of studies in the United States and internationally. 
Database and Biorepository Access  
The Clinical Core has established a database and biorepository. This Database includes nearly 1900 HIV-infected persons receiving care in the Duke University Adult Infectious Diseases Clinic and will soon include approximately 100 HIV-infected children and adolescents receiving care in the Pediatric Infectious Diseases Clinic.  The demographics of these patient populations mirror the reported demographics for North Carolina (57% African American and 28% women). There are currently over 70,000 plasma samples in this biorepository.

For more detailed information, please click here.
Community Engagement
The Clinical Core will work with the recently created Durham-Duke CFAR Collaborative Community Council to assist with important opportunities to interact with the community, receive feedback on study proposals and disseminate research results back to the community.

The Moshi Community Advisory Board at Kilimanjaro Christian Medical Centre (KCMC) meets monthly. They have separate meetings for a Youth CAB. The former Duke CFAR Community Advisory Board and the Moshi Community Advisory Board have been active within the National CFAR CAB Coalition in the past attending meetings in Philadelphia, Seattle and Boston and participating on conference calls. Bona Shirima is the Moshi CAB liaison. She has many years of experience working with the HIV- infected and HIV-affected communities.

Center for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS)

The Hemophilia Growth and Development Study (HGDS) data and specimens

NIH HIV Clinical Trials Networks Specimen Repository

Duke HIV Database and Biorepository

NIAID HIV/AIDS Specimen Repository Programs - Includes data and/or specimens from Multicenter AIDS Cohort Study (MACS) and Women's Interagency HIV Study (WIHS)

HIV and Heart Disease
Contextualizing Factors Associated with Non-adherence to Cardiovascular Disease Prevention Strategies for People Living with HIV who have Achieved Viral Suppression

Purposes: Visit 1 is being conducted to assess the rate of and factors associated with hypertension and hypercholesterolemia medication non-adherence among people living with HIV who have achieved HIV viral suppression (<200 copies/ml) at Duke Clinic 1K. Visit 2 is being conducted to describe the social-ecological context surrounding factors associated with hypertension and hypercholesterolemia medication non-adherence among people living with HIV who have achieved HIV viral suppression (<200 copies/ml) at Duke Clinic 1K.
Protocol Summary: A total of 60 people living with HIV who are seen in Duke Clinic 1K who take drugs for both hypertension and hypercholesterolemia will be enrolled. Enrollment/Visit 1 will consist of the informed consent process followed by the completion of an online survey related to how they take their hypertension and hypercholesterolemia drugs. This visit will be conducted by telephone. The visit should take about 25 minutes to complete. Some of these people will be contacted for an optional Visit 2 which will consist of a virtual or an in-person interview related to how they take their hypertension and hypercholesterolemia drugs. This visit may take 45 minutes to complete.
Eligibility: People living with HIV, 18 or older, fluent in English, competent to give informed consent who have achieved HIV viral suppression (<200 copies/ml) and are taking medications for hypertension and hypercholesterolemia.
Location: Enrollment/Visit 1 is virtual over the telephone. Optional Visit 2 is either virtual or at Duke Clinic 1K.
Contact: Stuart Carr, 919-668-4849

Addressing Barriers to Achieving Cardiometabolic Disorders Prevention and Treatment Goals for Persons Living with HIV in the Southeastern United States

Aim 1: To identify social determinants of cardiometabolic health and determine facilitators and modifiable barriers in achieving treatment goals utilizing in-depth interviews prompted by photo elicitation.
Aim 2: To assess knowledge, skills, and confidence for self-management of cardiometabolic disorders utilizing a Patient Activation Measure survey.
Aim 3: Guided by the Behavior Change Wheel model and using the human-centered design approach to tailor a self-management support and education intervention with stakeholder input to address barriers to achieving treatment goals for cardiometabolic disorders at the study sites.
Protocol Summary: A total of 140 people living with HIV who have one or more of the following conditions: hypertension, dyslipidemia, or type 2 diabetes and are seen in Duke Clinic 1K, or Amity Medical Group and Eastowne Family Physicians in Charlotte will be enrolled. AIM1: (20 participants) Enrollment/Visit 1 will consist of the informed consent process followed by the completion of an online demographic survey. This visit will be conducted in clinic. Participants will be trained in the use of the camera, the specific photo missions to be completed, and the ethics of photo elicitation. The visit should take about 45 minutes to complete. Visit 2: Participant will return the camera, select and caption photographs per specific photo missions that will be uploaded to secure server. This visit will be conducted in clinic and take approximately 30 minutes to complete. Visit 3: Virtual in-depth interview to discuss the content of the photographs and explore the facilitators and barriers to achieving heart health that are identified by the participant. AIM2: (120 participants) Enrollment/Visit 1: informed consent process followed by completion of Patient Activation Measure online survey. AIM3: (10 key stakeholders: HIV providers, CAB representatives, nurses, etc.) Enrollment/Visit 1-3: Informed consent process followed by 3 virtual meetings over 3 months. Each virtual meeting will last 3 hours, engaging participants in tailoring self-management support and education interventions at the study sites.
Eligibility: People living with HIV, 35 or older, fluent in English, competent to give informed consent who have one or more of the following conditions: hypertension, dyslipidemia, or type 2 diabetes.
Location: Duke Clinic 1K, and Amity Medical Group and Eastowne Family Physicians in Charlotte, NC
Contact: Duke: Laura Farrow, 919-668-0176 / Charlotte: Lalia Victoria 919-613-5430

Addressing barriers to anti-hypertensive medication adherence among persons living with HIV who have achieved viral suppression

Purpose: To determine key barriers and facilitators of antihypertensive medications adherence for people living with HIV who have achieved viral suppression
Protocol Summary: Study will enroll up to 20 PLWH to participate in interviews on barriers and facilitators of antihypertensive medication and up to 70 PLWH will be enrolled to complete a survey to determine salient barriers that an intervention must address in order to increase antihypertensive medications adherence for people living with HIV who have achieved viral suppression. Aim 1A enrollment will consist of the informed consent process followed by the completion of an interview related to understanding the barriers and facilitators to taking anti-hypertensive medication. Aim 1A visits will occur virtually over the phone or in person if preferred. This visit should take around 45 minutes to complete. Aim 1B enrollment will consist of the informed consent process followed by the completion of a Best/Worst Survey. The visit should take about 30 minutes to complete. Aim 1B will occur virtually and participants will receive a link to complete the survey.
Eligibility: People Living with HIV who have a suppressed HIV viral load (<200 copies/ml), hypertension (SBP >130mmHg on two occasions in the EMR within the last year and/or on anti-hypertensive medication), and on anti-hypertensive medication.
Location: Interviews will be conducted virtually over the phone on in a private room in 1K Clinic. Survey links will be sent virtually for the participant to complete.
Contact: Mersedes Brown, 919-668-7364

HIV and Cognitive Function

Purpose: HIV infection and marijuana use can each affect the immune system and the brain, which in turn may affect cognitive functioning (for example, memory, attention, reasoning). The purpose of this study is to determine the impact of marijuana use on these processes and the immune system in youth with HIV.
Protocol Summary: Most participants will have 1 visit. Visit 1 includes a screening, questionnaires, neuropsychological tests, and a blood draw. A subset of participants who complete Visit 1 will be asked to participate in Part 2, Immune Profiling and PET MR Scan at UNC.
Eligibility: 18-30 years old, living with HIV for at least one year, suppressed viral load and on ART for at least 6 months, last CD4 count above 350, willing to have blood draw
Location: Duke Clinic 1K
Contact: Ethan Bott, 919-684-2285

HIV Treatment Study for Minors
Gilead GS-US-380-1474

Purpose: The main purpose is to evaluate the pharmacokinetics (PK) for GS-9883 and confirm dose in this age population/weight band, and to evaluate its safety and tolerability.
Protocol Summary: This is a Phase 2 open label PK, safety, and antiviral activity of GS-9883/Emtricibine (F)/Tenofovir Alafenamide (TAF) fixed dose combination in HIV-1 infected virologically suppressed adolescents and children. There are two parts and four different age/weight groups (cohorts) to the study. Part A is 2 or 4 week intensive PK to evaluate the GS-9883 after which study participants will receive the GS-9883/F/TAF through a minimum of 48 weeks or until commercially available. Part B is treatment only phase. Subjects will receive GS-9883/F-TAF for a minimum of 48 weeks or until commercially available. Age cohort 1 (12 to less than 18 years of age will enroll into Part A and B. Age cohort 2 (6 to less than 12 years of age) will enroll into Part A and B. Age cohort 3 (2 to less than 12 and less than 25 kilograms) will be enrolled into Part A. Cohorts 1 and 2 Parts A and B have closed to accrual. Cohort 3 Parts A and B have closed to accrual. Cohort 4, Groups 1-4, will enroll into Part A and B.
Eligibility: Cohorts 1, 2 and 3 are closed. Cohort 4 only: Group 1: ≥ 2 years of age, weigh ≥ 14 to < 25 kg (≥ 31 to < 55 lbs.) and, taking a stable HIV treatment regimen and virologically suppressed (<50 copies/mL) for ≥ 6 months before screening, and unable to swallow tablets; Group 2:  ≥ 1 month of age, ≥ 10 to < 14 kg (≥ 22 to < 31 lbs.), ARV treatment naive or on ARV treatment for ≥ 1 month, Group 3: ≥ 1 month of age, ≥ 6 to < 10 kg (≥ 13 to < 22 lbs.), ARV treatment naive or on ARV treatment for ≥ 1 month and, Group 4: ≥ 1 month of age, ≥ 3 to < 6 kg (≥ 6.6 to < 13 lbs.), ARV treatment naive or on ARV treatment for ≥ 1 month. All 4 groups will initially receive the study drug in a “tablet for suspension” form which is easier to swallow than the regular study drug tablets.
Location: Duke Children’s Health Center
Contact: Stuart Carr, 919-668-4849
Enrollment: Currently on temporary hold.

Progression of cardiac structure and function in people with human immunodeficiency virus.
Bloomfield GS, Alenezi F, Chiswell K, Dunning A, Okeke NL, Velasquez EJ.
Echocardiography. 2022 Feb; 39 (2): 268-277
PMID: 35048419  
PMCID - not available yet

Cost-Effectiveness of Amphotericin B Deoxycholate Versus Itraconazole for Induction Therapy of Talaromycosis in Human Immunodeficiency Virus-Infected Adults in Vietnam
Buchanan J, Altunkaya J, Van Kinh N, Van Vinh Chau N, Trieu Ly V, Thi Thanh Thuy P, Hai Vinh V, Thi Hong Hanh D, Thuy Hang N, Phuong Thuy T, van Doorn R, Thwaites G, Gray A, Le T.
Open Forum Infect Dis. 2021 Jul 5;8(7):ofab357. doi: 10.1093/ofid/ofab357. eCollection 2021 Jul.
: 34337101   PMCID: PMC8320272

Understanding Retention in PrEP Care in the South: Insights from an Academic HIV Prevention Clinic
Burns CM, Borges M, Frye J, Keicher K, Elliott S, Schwartz S, Shipp K, Okeke NL, McKellar MS. AIDS Res Hum Retroviruses. 2022 Feb 16. doi: 10.1089/AID.2021.0177. Online ahead of print.
: 35172632   PMCID: PMC9048170

Effect of Haemophilus influenzae Type b and 13-Valent Pneumococcal Conjugate Vaccines on Childhood Pneumonia Hospitalizations and Deaths in Botswana
Congdon M, Hong H, Young RR, Cunningham CK, Enane LA, Arscott-Mills T, Banda FM, Chise M, Motlhatlhedi K, Feemster K, Patel SM, Boiditswe S, Leburu T, Shah SS, Steenhoff AP, Kelly MS. Clin Infect Dis. 2021 Jul 15;73(2):e410-e416. doi: 10.1093/cid/ciaa919.
PMID: 32634831   PMCID: PMC8282259

Sauti ya Vijana (SYV; The Voice of Youth): Longitudinal Outcomes of an Individually Randomized Group Treatment Pilot Trial for Young People Living with HIV in Tanzania
Dow DE, O'Donnell KE, Mkumba L, Gallis JA, Turner EL, Boshe J, Shayo AM, Cunningham CK, Mmbaga BT.
AIDS Behav. 2022 Jan 24;1-11. doi: 10.1007/s10461-021-03550-z. Online ahead of print.

PMID: 35067831   PMCID: PMC784208

An Extra Variable to Consider - Vaccine-Induced Seropositivity and Adolescent HIV Vaccine Clinical Trials
atola O, Corneli A, Perry B, Hanlen-Rosado E, Nsonwu A, Constantine EP, Thompson AB.
J Pediatric Infect Dis Soc. 2022 Feb 9;piac001. doi: 10.1093/jpids/piac001. Online ahead of print.
: 35139223   PMCID: PMC9155599

Feasibility and acceptability of a peer youth led curriculum to improve HIV knowledge in Northern Tanzania: resilience and intervention experience from the perspective of peer leaders
Hosaka KRJ, Mmbaga BT, Gallis JA, Dow DE.
BMC Public Health. 2021 Oct 23;21(1):1925. doi: 10.1186/s12889-021-11876-5.
PMC: 34688254   PMCID: PMC8542314

Perspectives of Black women in the United States on salon-based intervention to promote the uptake of pre-exposure prophylaxis (PrEP) for HIV
Johnson R, Myers D, McKellar M, Saint-Hillaire L, Randolph SD.
J Clin Nurs. 2021 Nov;30(21-22):3281-3289. doi: 10.1111/jocn.15838. Epub 2021 May 9.
: 33969573   PMCID: PMC8500915

Non-diphtheriae Corynebacterium species are associated with decreased risk of pneumococcal colonization during infancy
Kelly MS, Plunkett C, Yu Y, Aquino JN, Patel SM, Hurst JH, Young RR, Smieja M, Steenhoff AP, Arscott-Mills T, Feemster KA, Boiditswe S, Leburu T, Mazhani T, Patel MZ, Rawls JF, Jawahar J, Shah SS, Polage CR, Cunningham CK, Seed PC.
ISME J. 2022 Mar;16(3):655-665. doi: 10.1038/s41396-021-01108-4. Epub 2021 Sep 11.
PMC: 34511605   PMCID: PMC8857224

Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus
Kileel EM, Lo J, Malvestutto C, Fitch KV, Zanni MV, Fichtenbaum CJ, Overton ET, Okeke NL, Kumar P, Joao E, Aberg JA, Martinez E, Currier JS, Douglas PS, Ribaudo HJ, Grinspoon SK.
Open Forum Infect Dis. 2021 Nov 20;8(12):ofab537.

PMC: 34888395   PMCID: PMC8651160

HIV Stigmatizing Attitudes Among Men Accompanying Their Partners to Antenatal Care in Tanzania: A Mixed-Method Study
Kisigo GA, Ngocho JS, Mwamba RN, Knettel BA, Relf MV, Mmbaga BT, Watt MH.
AIDS Behav. 2021 Apr 21. doi: 10.1007/s10461-021-03264-2.

PMC: 33881647   PMCID: PMC8788108

Prognosis and treatment effects of HIV-associated talaromycosis in a real-world patient cohort
Klus J, Ly VT, Chan C, Le T.
Med Mycol. 2021 Apr 6;59(4):392-399. doi: 10.1093/mmy/myab005.

PMC: 33644813   PMCID: PMC8023982

HIV, cancer, and coping: The cumulative burden of a cancer diagnosis among people living with HIV
Knettel B, Corrigan K, Cherenack E, Ho N, Carr S, Cahill J, Chino J, Ubel P, Watt M, Suneja G.

J Psychosoc Oncol. 2021;39(6):734-748. doi: 10.1080/07347332.2020.1867691. Epub 2021 Jan 6.
PMC: 33407058   PMCID: PMC8397369

The Role of Community Health Workers in HIV Care Engagement: A Qualitative Study of Stakeholder Perspectives in Tanzania
Knettel BA, Fernandez KM, Wanda L, Amiri I, Cassiello-Robbins C, Watt MH, Mmbaga BT, Relf MV.
J Assoc Nurses AIDS Care. 2021 Apr 27:10.1097/JNC.0000000000000267. doi: 10.1097/JNC.0000000000000267.

PMC: 33908407   PMCID: PMC8548405

Assessing the Influence of Community Health Worker Support on Early Antiretroviral Therapy Adherence, Anticipated Stigma, and Mental Health Among People Living with HIV in Tanzania
Knettel BA, Wanda L, Amiri I, Myers J, Fernandez KM, Muiruri C, Watt MH, Mmbaga BT, Relf MV.
AIDS Patient Care STDS. 2021 Aug;35(8):308-317. doi: 10.1089/apc.2021.0028.
PMC: 34375138   PMCID: PMC8380803

Patient perspectives on the helpfulness of a community health worker program for HIV care engagement in Tanzania
Knettel BA, Muhirwa A, Wanda L, Amiri I, Muiruri C, Fernandez KM, Watt MH, Mmbaga BT, Relf MV.
AIDS Care. 2021 Oct 26:1-8. doi: 10.1080/09540121.2021.1995840. Online ahead of print.
PMC: 34702095   PMCID: PMC9038954

Attitudes Toward Pregnancy Among Women Enrolled in Prevention of Mother-to-Child Transmission of HIV (PMTCT) Services in Moshi, Tanzania
Knippler ET, Mwamba RN, Coleman JN, Knettel BA, Minja LM, Kisigo GA, Ngocho JS, Cichowitz C, Mmbaga BT, Watt MH.
IDS Behavior 2021 Dec;25(12):4008-4017. doi: 10.1007/s10461-021-03339-0. Epub 2021 Jun PMC: 34125322   PMCID - not available yet

Frequent development of broadly neutralizing antibodies in early life in a large cohort of children living with HIV
Lucier A, Fong Y, Li SH, Dennis M, Eudailey J, Nelson A, Saunders K, Cunningham CK, McFarland E, McKinney R, Moody MA, LaBranche C, Montefiori D, Permar SR, Fouda GG.
J Infect Dis. 2021 Dec 28;jiab629. doi: 10.1093/infdis/jiab629. Online ahead of print.
PMC: 34962990   PMCID: PMC9113503

International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) P1112 Team. Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants
McFarland EJ, Cunningham CK, Muresan P, Capparelli EV, Perlowski C, Morgan P, Smith B, Hazra R, Purdue L, Harding PA, Theron G, Mujuru H, Agwu A, Purswani M, Rathore MH, Flach B, Taylor A, Lin BC, McDermott AB, Mascola JR, Graham BS.
J Infect Dis. 2021 Dec 1;224(11):1916-1924. doi: 10.1093/infdis/jiab229.
PMC: 34009371   PMCID: PMC8643399

Comparison of Predicted Cardiovascular Risk Profiles by Different CVD Risk-Scoring Algorithms between HIV-1-Infected and Uninfected Adults: A Cross-Sectional Study in Tanzania
Msoka T, Rogath J, Van Guilder G, Kapanda G, Smulders Y, Tutu van Furth M, Bartlett J, van Agtmael M.
HIV AIDS (Auckl). 2021 Jun 3;13:605-615. doi: 10.2147/HIV.S304982. eCollection 2021.
PMC: 34113177   PMCID: PMC8184149

Pulmonary Talaromycosis: A Window into the Immunopathogenesis of an Endemic Mycosis
Narayanasamy S, Dougherty J, van Doorn HR, Le T. Mycopathologia.
2021 Oct;186(5):707-715. doi: 10.1007/s11046-021-00570-0. Epub 2021 Jul 6.
PMC: 34228343   PMCID: PMC8536569

A global call for talaromycosis to be recognised as a neglected tropical disease
Narayanasamy S, Dat VQ, Thanh NT, Ly VT, Chan JF, Yuen KY, Ning C, Liang H, Li L, Chowdhary A, Youngchim S, Supparatpinyo K, Aung NM, Hanson J, Andrianopoulos A, Dougherty J, Govender NP, Denning DW, Chiller T, Thwaites G, van Doorn HR, Perfect J, Le T.
Lancet Glob Health. 2021 Nov;9(11):e1618-e1622.
PMC: 34678201   PMCID - not available yet

Prevalence of Multidrug Resistant UTI Among People Living with HIV in Northern Tanzania
Ngowi BN, Sunguya B, Herman A, Chacha A, Maro E, Rugarabamu LF, Bartlett J, Balandya E, Mteta KA, Mmbaga BT.
Infect Drug Resist. 2021 Apr 22;14:1623-1633. doi: 10.2147/IDR.S299776. eCollection 2021.
PMC: 33911886   PMCID: PMC8075732

Adolescent mental health research in Tanzania: a study protocol for a priority setting exercise and the development of an interinstitutional capacity strengthening programme
Obasi A, Seekles M, Boshe J, Dow D, Mmbaga B, Ngakongwa F, Okello E, Renju J, Shayo E, Simbee G, Todd J, Oriyo N.
BMJ Open 2022 Feb 2;12(2):e054163. doi: 10.1136/bmjopen-2021-054163.
PMC: 35110319    PMCID: PMC8811585

Awareness and acceptability of HIV pre-exposure prophylaxis (PrEP) among students at two historically Black universities (HBCU): a cross-sectional survey
Okeke NL, McLaurin T, Gilliam-Phillips R, Wagner DH, Barnwell VJ, Johnson YM, James O, Webb PB, Parker SD, Hill B, McKellar MS, Mitchell JT.
BMC Public Health. 2021 May 19;21(1):943. doi: 10.1186/s12889-021-10996-2.
PMC: 34006245   PMCID: PMC8132367

Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine
Patel SM, Shaik-Dasthagirisaheb YB, Congdon M, Young RR, Patel MZ, Mazhani T, Boiditswe S, Leburu T, Lechiile K, Arscott-Mills T, Steenhoff AP, Feemster KA, Shah SS, Cunningham CK, Pelton SI, Kelly MS.
PLoS One. 2022 Jan 5;17(1):e0262225. doi: 10.1371/journal.pone.0262225. eCollection 2022.
PMC: 34986196   PMCID: PMC8730465

Neurocognitive trajectories after 72 weeks of first-line anti-retroviral therapy in Vietnamese adults with HIV-HCV co-infection
Paul RH, Shikuma C, Vinh Chau NV, Ndhlovu LN, Thanh NT, Belden AC, Chow DC, Chew GM, Premeaux TA, Ly VT, McBride JAD, Bolzenius JD, Le T.
Frontiers Neurology. 021 Mar 12;12:602263. doi: 10.3389/fneur.2021.602263. eCollection 2021.
PMC: 33776879   PMCID: PMC7996090

Do Women Enrolled in PMTCT Understand the Recommendations: A Case Study from Kilimanjaro
Philemon RN, Mmbaga BT, Bartlett J, Renju J, Mtuy T, Mboya IB, Msuya SE.
Patient Prefer Adherence. 2021 Jun 16;15:1301-1309. doi: 10.2147/PPA.S307847. eCollection 2021.
PMC: 34163147   PMCID: PMC8216065

Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in Vietnam
Shikuma CM, Le T, Phuong TV, Chew GM, Nguyen VVC, Vo TL, Siriwardhana C, Chow D, Ghukasyan H, Limpruttidham N, Premeaux T, Gangcuangco LM, Paul R, Ndhlovu LC.
AIDS Res Hum Retroviruses. 2022 Jan 13. doi: 10.1089/AID.2021.0076. Online ahead of print.
PMC: 34861767   PMCID: not available yet

Population Pharmacokinetics and Pharmacodynamics of Itraconazole for Disseminated Infection Caused by Talaromyces marneffei
Stott KE, Le T, Nguyen T, Whalley S, Unsworth J, Ly VT, Kolamunnage-Dona R, Hope W. Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0063621. doi: 10.1128/AAC.00636-21. Epub 2021 Aug 9.
PMC: 34370587   PMCID: PMC8522747

Global Guidelines for the Diagnosis and Management of the Endemic Mycoses an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology
Thompson GR, Le T, Chindamporn A, et al.
Lancet Infec Dis. 2021 Dec;21(12):e364-e374. doi: 10.1016/S1473-3099(21)00191-2. Epub 2021 Aug 6.
PMC: 34364529   PMCID - not available yet

Examining the Potential of Pre-exposure Prophylaxis (PrEP) for HIV Prevention in a Community Sample of Persons Who Use Stimulants Living in the Southern United States
Towe SL, Sullivan CA, McKellar MS, Meade CS.
AIDS Behav. 2021 May;25(5):1480-1489. doi: 10.1007/s10461-020-02987-y.
PMC: 32757101   PMCID: PMC7862414

Talaromyces marneffei promotes M2-like polarization of human macrophages by downregulating SOCS3 expression and activating the TLR9 pathway
Wei W, Ning C, Huang J, Wang G, Lai J, Han J, He J, Zhang H, Liang B, Liao Y, Le T, Luo Q, Li Z, Jiang J, Ye L, Liang H.
Virulence. 2021 Dec;12(1):1997-2012. doi: 10.1080/21505594.2021.1958470.
PMC: 34339354   PMCID: PMC8331029

Dorothy Dow

Dorothy Dow, M.D.
Clinical Core Co-Director

Thuy Le

Thuy Le, M.D., Ph.D.
Clinical Core Co-Director
(919) 668-5053

Lance Okeke

Dr. Nwora Lance Okeke
Associate Director
(919) 684-2597

Mehri McKellar

Dr. Mehri McKellar
Community Liaison
(919) 613-6129

Stuart Carr

Stuart Carr
Clinical Core Research Program Leader
(919) 668-4849

Kathy Link

Katherine Link, RN
Clinical Core Regulatory Manager
(919) 668-0161

John Bartlett

John Bartlett, MD

Clinical Core group email: